Best Options Strategy for DNLI
Looking for the best options strategy for Denali Therapeutics Inc. (DNLI)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live DNLI option chain right now, and a simple map from your view on DNLI to the strategy that fits it. Model any of them in the calculator before you trade.
About DNLI
Denali Therapeutics Inc. (DNLI) is a major company in Biotechnology. Options traders on DNLI tend to watch , since these can drive large moves in the share price.
About Denali Therapeutics Inc.
Denali Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for neurodegenerative and lysosomal storage diseases. Its pipeline spans multiple therapeutic approaches, including small-molecule inhibitors targeting specific disease pathways—such as RIPK1 and LRRK2 inhibitors for inflammatory and Parkinson's-related conditions—and protein replacement therapies designed to address enzyme deficiencies. The company has also developed a proprietary Enzyme TransportVehicle platform technology that enhances drug delivery to the central nervous system, which it applies across programs targeting conditions like Pompe disease, Gaucher disease, Hurler syndrome, and various forms of neurodegeneration including Alzheimer's and Parkinson's diseases.
The company generates revenue through partnerships and collaborative arrangements with larger pharmaceutical firms. Denali has established agreements with major players like Roche and Takeda that involve upfront payments, milestone achievements, and royalties on future sales of developed therapies. As of its incorporation in 2013 and rebranding from SPR Pharma in 2015, the company operates from South San…
Today's top-scoring strategy for DNLI
Our engine ranks defined-risk strategies on the live DNLI chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $23 | $0.03 |
| Sell | 1× | PUT | $24 | $0.13 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at DNLI's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
DNLI is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on DNLI currently price in about 32% implied volatility, versus roughly 45% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$1.62 (±6%) in DNLI by 2026-07-17 — a range of roughly $24.01 to $27.25. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on DNLI trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Key figures
- Market cap
- $4.1B
- Beta (vs market)
- 1.01
- 52-week range
- $12.58–$26.80 (92% up the range)
- Short interest
- 10.3% of float · 8.2 days to cover
With 10.3% of DNLI's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for DNLI
Start with your outlook on DNLI, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while DNLI stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open DNLI in the free calculator →
Frequently asked questions
What is the best options strategy for DNLI?
It depends on your outlook. Bullish traders often use a long call or bull call spread on DNLI; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are DNLI options liquid enough to trade?
Denali Therapeutics Inc. (DNLI) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade DNLI options?
Buying a single DNLI call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade DNLI or any security. Do your own research.
What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc. (DNLI) operates in the Biotechnology industry. The "About Denali Therapeutics Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Denali Therapeutics Inc. pay a dividend?
Denali Therapeutics Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
Tickers related to DNLI
Comparing DNLI with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 161 Oyster Point Boulevard, South San Francisco, CA, 94080, United States
- Industry
- Biotechnology
- Employees
- 507
- CEO
- Dr. Ryan J. Watts Ph.D.
- Phone
- 650 866 8547
- Website
- www.denalitherapeutics.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.